Want to see DOCS full AI Analyst Report?
DOCS Stock Chart & Stats
$24.71
-$0.33(-0.59%)
At close: 4:00 PM EST
$24.71
-$0.33(-0.59%)
Day’s Range― - ―
52-Week Range$17.15 - $76.51
Previous CloseN/A
Volume296.07K
Average Volume (3M)3.18M
Market Cap
$3.87B
Enterprise Value$3.81K
Total Cash (Recent Filing)$748.60M
Total Debt (Recent Filing)$10.19M
Price to Earnings (P/E)20.9
Beta1.46
Next Earnings
Aug 06, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.04
Shares Outstanding128,856,930
10 Day Avg. Volume2,501,858
30 Day Avg. Volume3,180,629
Financial Highlights & Ratios
PEG Ratio-1.89
Price to Book (P/B)4.58
Price to Sales (P/S)6.76
P/FCF Ratio13.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$24.82Price Target Upside0.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)1.43
Revenue Forecast (FY)$669.95M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a large capital base materially lower financial risk and preserve strategic optionality. Over the next 2–6 months this allows Doximity to fund AI R&D, repurchases, or M&A without refinancing pressure, supporting long‑term investment flexibility.
Robust Cash GenerationConsistent, high free cash conversion provides durable internal funding for growth investments and shareholder returns. Strong cash flows reduce reliance on external capital and enable multi‑quarter execution of AI initiatives while maintaining liquidity and capital allocation optionality.
Sticky Enterprise Revenue & RetentionHigh NRR and a growing cohort of large customers point to entrenched, subscription‑style revenue that supports predictability and upsell. Enterprise adoption lowers churn risk and provides a stable base to scale new products like clinical AI over the medium term.
Bears Say
Near-term Revenue SlowdownManagement's materially lower growth guidance signals a deceleration in top‑line momentum that could persist for several quarters. Slower organic growth tightens the timeframe for ROI on AI investments and increases dependence on product expansion and enterprise upsells to regain higher growth.
Margin Pressure From AI InvestmentA deliberate ramp in AI compute, R&D, and marketing plus elevated stock‑based comp will compress margins near term. Even with management targeting high‑40s adjusted EBITDA, sustained higher operating spend could reduce free cash flow and shareholder return capacity over the next several quarters.
Booking Visibility & Customer ConcentrationOnly partial booking coverage and macro/policy headwinds reduce revenue visibility and make forecasting harder. Heavy revenue concentration in a limited set of large customers further amplifies downside risk if those customers cut spending or delay campaigns over the next 2–6 months.
Doximity News
DOCS FAQ
What was Doximity, Inc.’s price range in the past 12 months?
Doximity, Inc. lowest stock price was $17.15 and its highest was $76.51 in the past 12 months.
What is Doximity, Inc.’s market cap?
Doximity, Inc.’s market cap is $3.87B.
When is Doximity, Inc.’s upcoming earnings report date?
Doximity, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Doximity, Inc.’s earnings last quarter?
Doximity, Inc. released its earnings results on May 13, 2026. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.283 by -$0.023.
Is Doximity, Inc. overvalued?
According to Wall Street analysts Doximity, Inc.’s price is currently Undervalued.
Does Doximity, Inc. pay dividends?
Doximity, Inc. does not currently pay dividends.
What is Doximity, Inc.’s EPS estimate?
Doximity, Inc.’s EPS estimate is 0.3.
How many shares outstanding does Doximity, Inc. have?
Doximity, Inc. has 128,856,930 shares outstanding.
What happened to Doximity, Inc.’s price movement after its last earnings report?
Doximity, Inc. reported an EPS of $0.26 in its last earnings report, missing expectations of $0.283. Following the earnings report the stock price went down -23.001%.
Which hedge fund is a major shareholder of Doximity, Inc.?
Currently, no hedge funds are holding shares in DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Doximity Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.82 (0.46% Upside)
$24.82 (0.46% Upside)
Blogger Sentiment
Bullish
DOCS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 112.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.00%
Trailing 12-Months
Company Description
Doximity, Inc.
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
DOCS Revenue Breakdown
93.00% Subscription
7.00% Other
DOCS Stock 12 Month Forecast
Average Price Target
$24.82
▲(0.46% Upside)
Technical Analysis
Omnicell
―
Evolent Health
―
Teladoc
―
Definitive Healthcare Corp
―
Tempus AI, Inc. Class A
―
Ownership Overview
3.05% Insiders
26.43% Mutual Funds
0.92% Other Institutional Investors
47.25% Public Companies and Individual Investors